

Caple supports Biopharma Group's acquisition of Easytesters with a long-term, £1.25m loan

Caple has supported the acquisition of Easytesters by the Biopharma Group with a long-term, unsecured loan.

The Biopharma Group of companies operate in the pharmaceutical services industry, principally relating to protein stabilisation. The Group sells diagnostics and processing equipment, maintenance / service services and consultancy services to a broad cross section of their international market. The eight year, fully unsecured loan will fund the acquisition of Easytesters Ltd, a hazard analysis testing technology company. The acquisition of Easytesters provides the enlarged group with significant cross-selling and diversification opportunities.

The fully unsecured loan required no security, allowing the Group to maintain their existing facilities with their incumbent lender, Lloyds Banking Group. No intercreditor agreements were required between lenders and the 8-year tenor provides significant cash flow flexibility to allow for integration of the acquired business.

"The Caple facility, with an 8 year term, was an ideal funding solution for Biopharma, allowing them to initially integrate and then invest in the growth of Easytesters, without the cashflow pressures of more traditional, shorter term, banking facilities"

Andy Coghlan, Partner - WK Corporate Finance

"Acquisition finance is a key part of many successful companies' growth strategy. For the Biopharma Group, finance that did not disturb existing working capital facilities and had a tenor that provided cash flow flexibility has resulted in a great outcome for the business"

Sean Brophy, Country Manager, Caple